(Q34458907)

2 August 2017

0 references

Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer (English)

1 reference

2 August 2017

1 reference

1 reference

1

Joanne L Blum

1 reference

2 August 2017

Carlos H Barrios

2

1 reference

2 August 2017

Nancy Feldman

3

1 reference

2 August 2017

Sunil Verma

4

1 reference

2 August 2017

Edward F McKenna

5

1 reference

2 August 2017

Luen F Lee

6

1 reference

2 August 2017

Nana Scotto

7

1 reference

2 August 2017

Julie Gralow

8

1 reference

2 August 2017

language of work or name

English

0 references

publication date

27 October 2012

1 reference

Breast Cancer Research and Treatment

2 August 2017

1 reference

2 August 2017

136

1 reference

2 August 2017

3

1 reference

2 August 2017

777-788

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-012-2288-x

2 August 2017

0 references

cites work

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Safety of capecitabine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2288-X

10.1007/S10549-012-2288-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference